(NASDAQ: FULC) Fulcrum Therapeutics's forecast annual revenue growth rate of 198.01% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.19%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Fulcrum Therapeutics's revenue in 2024 is $2,510,000.On average, 2 Wall Street analysts forecast FULC's revenue for 2024 to be $4,972,291,040, with the lowest FULC revenue forecast at $4,972,291,040, and the highest FULC revenue forecast at $4,972,291,040. On average, 1 Wall Street analysts forecast FULC's revenue for 2025 to be $2,043,611,617, with the lowest FULC revenue forecast at $2,043,611,617, and the highest FULC revenue forecast at $2,043,611,617.
In 2026, FULC is forecast to generate $5,243,280,902 in revenue, with the lowest revenue forecast at $5,243,280,902 and the highest revenue forecast at $5,243,280,902.